BofI Federal Bank Signs Agreement to Acquire $3 Billion of Deposits from Nationwide Bank

SAN DIEGO–()–BofI Holding, Inc. (NASDAQ: BOFI) (the “Company”), parent of BofI Federal Bank (“BofI” or the “Bank”), announced today that the Bank has signed a deposit purchase and assumption agreement (“DAA”) with Nationwide Bank to acquire approximately $3 billion in deposits from Nationwide Bank, including $1 billion in checking, savings and money market accounts and $2 billion in time deposit accounts. BofI and Nationwide Bank expect to receive regulatory approval and complete the deposit acquisition and transfer during the fourth quarter of 2018.

“We are excited to welcome Nationwide Bank’s nearly 100,000 deposit customers to BofI,” began Gregory Garrabrants, President and Chief Executive Officer of BofI Holding, Inc. “Our track record of successfully completing similar transactions with Principal Bank and H&R Block provide us with a high degree of confidence that we will have a seamless transition. We look forward to offering Nationwide Bank customers our full suite of consumer, commercial and small business banking products and services once the transaction closes.”

“BofI is a strong and stable institution with many similarities to Nationwide Bank. Both companies are direct, digital banks with a customer-centric approach to banking,” said Terrance Williams, Chief Marketing Officer and President of Emerging Businesses for Nationwide. “Because of these similarities, as well as BofI’s depth of product offerings and history of successful transitions, we feel confident that it’s the right partner to provide banking services to our customers going forward.”

A deposit premium commensurate with the fair market value of the deposits purchased will be funded from excess capital at the Bank. The Company expects the transaction to be immediately accretive to earnings and tangible book value.

About Nationwide

Nationwide, a Fortune 100 company based in Columbus, Ohio, is one of the largest and strongest diversified insurance and financial services organizations in the U.S. and is rated A+ by both A.M. Best and Standard & Poor’s. The company provides a full range of insurance and financial services, including auto, commercial, homeowners, farm and life insurance; public and private sector retirement plans, annuities and mutual funds; banking and mortgages; excess & surplus, specialty and surety; pet, motorcycle and boat insurance. For more information, visit www.nationwide.com.

About BofI Holding, Inc.

BofI Holding, Inc. (NASDAQ: BOFI) is the holding company for BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small-to-medium size businesses in target sectors, and selected specialty finance receivables. With approximately $9.5 billion in assets, BofI Federal Bank provides consumer and business banking products through its low-cost distribution channels and affinity partners. BofI Holding, Inc.’s common stock is listed on the NASDAQ Global Select Market under the symbol “BOFI” and is a component of the Russell 2000® Index, the S&P SmallCap 600® Index, and the KBW Nasdaq Financial Technology Index. For more information on BofI Federal Bank, please visit bofifederalbank.com.

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements that involve risks and uncertainties, including without limitation statements relating to BofI and Nationwide Bank’s receipt of regulatory approval and ability to complete the deposit transaction, BofI’s financial prospects and other projections of its performance and asset quality, BofI’s ability to grow and increase its business, diversify its lending, and the anticipated timing and financial performance of new initiatives. These forward-looking statements are made on the basis of the views and assumptions of management regarding future events and performance as of the date of this press release. Actual results and the timing of events could differ materially from those expressed or implied in such forward-looking statements as a result of risks and uncertainties, including without limitation our ability to successfully combine and integrate the assumed deposits from Nationwide Bank and our ability to do so without disrupting our ongoing business. These and other risks and uncertainties detailed in BofI’s periodic reports filed with the Securities and Exchange Commission could cause actual results to differ materially from those expressed or implied in any forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and BofI undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

http://www.businesswire.com/news/home/20180803005124/en/BofI-Federal-Bank-Signs-Agreement-Acquire-3/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

vTv Therapeutics Announces Second Quarter 2018 Results and Update

HIGH POINT, N.C.–()–vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2018, and provided an update on recent achievements and upcoming events.

“Since our announcement regarding the topline results from Part B of the STEADFAST Study, we have continued to analyze the results from Parts A and B and are encouraged by our findings,” said Steve Holcombe, chief executive officer, vTv Therapeutics. “In addition, our other programs, including our glucokinase activator currently in clinical development for type 1 diabetes and our GLP-1R program that is being developed in partnership with Huadong Medicine for type 2 diabetes, continue to make steady progress.”

Recent Achievements and Outlook

  • Azeliragon data analysis continues in order to move development of the therapy forward in consultation with our scientific advisory board and the FDA.
  • SimplicT-1 Study enrolling patients with type 1 diabetes. The adaptive Phase 1/2 SimplicT-1 Study has begun dosing patients with type 1 diabetes in a 12 week study to evaluate TTP399 as an add-on to insulin therapy. TTP399 has previously demonstrated statistically significant reductions in HbA1c levels in the AGATA Study, a phase 2 study in type 2 diabetes.
  • Advancing PDE4 program with Newsoara. During the second quarter, vTv licensed rights to its PDE4 program to Newsoara Biopharma Co., Ltd. to further its development and potential commercialization in China and other Pacific Rim countries. Newsoara is developing vTv’s PDE4 compounds as a potential therapeutic for COPD, a chronic illness affecting nearly 100 million people in China.
  • Additional Investment by MacAndrews & Forbes Incorporated. MacAndrews & Forbes provided vTv an additional $10 million capital line.

Upcoming Events

vTv will participate in the following upcoming investor conferences:

vTv will also participate in the following upcoming scientific conferences:

  • 11th Clinical Trials on Alzheimer’s Disease (CTAD), October 24-27, Barcelona.

Second Quarter 2018 Financial Results

  • Cash Position: Cash and cash equivalents as of June 30, 2018, were $1.2 million compared to $6.5 million as of March 31, 2018.
  • R&D Expenses: Research and development expenses were $8.6 million in the second quarter of 2018, compared to $8.9 million in the first quarter of 2018. The decrease in research and development expenses was primarily driven by the termination of the STEADFAST and open label extension studies during the second quarter of fiscal 2018.
  • G&A Expenses: General and administrative expenses were $2.7 million and $2.3 million, for the second quarter of 2018 and the first quarter of 2018, respectively. The change in general and administrative cost was driven by lower incentive compensation costs in the first quarter of 2018 related to a reduction in the expected probability of payment of the remaining amount of fiscal 2017 incentive bonuses.
  • Net Loss Before Non-Controlling Interest: Net loss before non-controlling interest was $9.6 million for the second quarter of 2018 compared to net loss before non-controlling interest of $10.0 million for the first quarter of 2018.
  • Net Loss per Share: GAAP net loss per share was $0.31 and $0.30 for the three months ended June 30, 2018 and March 31, 2018, respectively, based on weighted-average shares of 10.0 million and 9.7 million for the three month periods ended June 30, 2018 and March 31, 2018, respectively. Non-GAAP net loss per fully exchanged share was $0.29 and $0.30 for the three months ended June 30, 2018 and March 31, 2018, respectively, based on non-GAAP fully exchanged weighted-average shares of 33.1 million and 32.8 million for the three months ended June 30, 2018 and March 31, 2018, respectively.

 

       

vTv Therapeutics Inc.

Condensed Consolidated Balance Sheets – Unaudited

(in thousands)

 
June 30, March 31,
2018 2018
 
Assets
Current assets:
Cash and cash equivalents $ 1,163 $ 6,535
Restricted cash and cash equivalents
Accounts receivable, net 2,270 210
Prepaid expenses and other current assets 264 471
Current deposits   2,311     2,256  
Total current assets 6,008 9,472
Restricted cash and cash equivalents, long-term 2,500 2,500
Property and equipment, net 202 241
Long-term investments 2,480 2,480
Long-term deposits   36     36  
Total assets $ 11,226   $ 14,729  
Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Deficit
Current liabilities:
Accounts payable and accrued expenses $ 13,144 $ 11,296
Current portion of deferred revenue 10,114 8,754
Current portion of notes payable   8,229     6,771  
Total current liabilities 31,487 26,821
Notes payable 10,863 13,091
Deferred revenue, net of current portion 603 2,436
Warrant liability, related party 201 517
Other liabilities   256     255  
Total liabilities 43,410 43,120
Commitments and contingencies
Redeemable noncontrolling interest 39,413 120,397
Stockholders’ deficit:
Class A Common Stock 109 97
Class B Common Stock 232 232
Additional paid-in capital 134,587 128,796
Accumulated deficit   (206,525 )   (277,913 )
Total stockholders’ deficit attributable to vTv Therapeutics Inc.   (71,597 )   (148,788 )
Total liabilities, redeemable noncontrolling interest and stockholders’ deficit $ 11,226   $ 14,729  
 
   

vTv Therapeutics Inc.

Condensed Consolidated Statements of Operations – Unaudited

(in thousands, except per share data)

 
Three Months Ended
June 30, 2018     March 31, 2018
Revenue $ 2,473 $ 2,064
Operating expenses:
Research and development 8,594 8,943
General and administrative   2,737     2,255  
Total operating expenses   11,331     11,198  
Operating loss (8,858 ) (9,134 )
Interest income 16 18
Interest expense (870 ) (855 )
Other income (expense), net   316     11  
Loss before income taxes and noncontrolling interest (9,396 ) (9,960 )
Income tax provision   200      
Net loss before noncontrolling interest (9,596 ) (9,960 )
Less: net loss attributable to noncontrolling interest   (6,524 )   (7,008 )
Net loss attributable to vTv Therapeutics Inc. $ (3,072 ) $ (2,952 )
Net loss per share of vTv Therapeutics Inc. Class A

Common Stock, basic and diluted

$ (0.31 ) $ (0.30 )
Weighted-average number of vTv Therapeutics Inc.

Class A Common Stock, basic and diluted

  10,049,831     9,699,721  
 
       

vTv Therapeutics Inc.

Condensed Consolidated Statements of Operations – Unaudited

(in thousands, except per share data)

 
Three Months Ended June 30,

For the Six Months Ended June 30,

2018     2017 2018     2017
Revenue $ 2,473 $ 13 $ 4,537 $ 43
Operating expenses:
Research and development 8,594 9,623 17,537 20,583
General and administrative   2,737     3,005     4,992     5,829  
Total operating expenses   11,331     12,628     22,529     26,412  
Operating loss (8,858 ) (12,615 ) (17,992 ) (26,369 )
Interest income 16 33 34 60
Interest expense (870 ) (832 ) (1,725 ) (1,391 )
Other income (expense), net   316         327      
Loss before income taxes and noncontrolling interest (9,396 ) (13,414 ) (19,356 ) (27,700 )
Income tax provision   200         200      
Net loss before noncontrolling interest (9,596 ) (13,414 ) (19,556 ) (27,700 )
Less: net loss attributable to noncontrolling interest   (6,524 )   (9,451 )   (13,532 )   (19,517 )
Net loss attributable to vTv Therapeutics Inc. $ (3,072 ) $ (3,963 ) $ (6,024 ) $ (8,183 )
Net loss per share of vTv Therapeutics Inc. Class A Common

Stock, basic and diluted

$ (0.31 ) $ (0.41 ) $ (0.61 ) $ (0.84 )
Weighted-average number of vTv Therapeutics Inc. Class A

Common Stock, basic and diluted

  10,049,831     9,693,254     9,875,743     9,693,254  
 

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflammatory disorders.

About STEADFAST

The STEADFAST study, two independent and identical randomized, double-blind, placebo-controlled Phase 3 trials (Part A and Part B), was designed to investigate the safety and efficacy of azeliragon as a potential treatment for patients with mild Alzheimer’s disease. The 18-month study targeted enrollment of 800 patients (400 in each trial). The first trial enrolled patients in the United States and Canada who had a clinical diagnosis of mild Alzheimer’s disease and an MRI consistent with this diagnosis. Enrollment of the second trial included study sites in the United Kingdom, Ireland, Australia, New Zealand and South Africa. Clinical trials involving azeliragon, including the Part B Study and the open-label extension study have been terminated based on the topline results from the Part A Study showing the trial failed to meet either of the co-primary endpoints. Topline efficacy results from the Part B Study were announced in June of 2018 showing that this trial also failed to meet either of the co-primary endpoints.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.

Non-GAAP Financial Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the U.S. (“GAAP”), we use non-GAAP earnings per fully exchanged share, which is a non-GAAP financial measure. Non-GAAP earnings per fully exchanged share is defined as net loss attributable to vTv Therapeutics Inc. including the loss attributable to the non-controlling interest and assuming the exchange of all the Class B common stock of vTv Therapeutics Inc. and an equal number of non-voting common units of vTv Therapeutics LLC (“vTv Units”) for shares of Class A common stock of vTv Therapeutics Inc. We believe that this measure provides useful information to investors as it eliminates the variability of non-controlling interest resulting from the exchanges of Class B common stock and vTv Units into Class A common stock. This measure is not intended to be considered in isolation or as a substitute for, or superior to, financial measures prepared and presented in accordance with GAAP.

The following is a reconciliation of non-GAAP earnings per fully exchanged share, basic and diluted to its most directly comparable GAAP measure, net loss per share of vTv Therapeutics Class A common stock, basic and diluted and the computation of the components of this non-GAAP measure:

   
Three Months Ended
June 30, 2018     March 31, 2018
Numerator:
Net loss attributable to vTv Therapeutics Inc. $ (3,072 ) $ (2,952 )
Reallocation of net income attributable to non-controlling

interest from the assumed exchange of Class B shares (1)

  (6,524 )   (7,008 )
Net loss before noncontrolling interest $ (9,596 ) $ (9,960 )
Denominator:
Weighted-average number of vTv Therapeutics Inc.

Class A Common Stock, basic and diluted

10,049,831 9,699,721
Assumed exchange of Class B Common Stock (1)   23,094,221     23,115,631  
Adjusted proforma fully exchanged weighted-average

shares of Class A common stock outstanding,

basic and diluted

  33,144,052     32,815,352  
Adjusted proforma earnings per fully exchanged share,

basic and diluted

$ (0.29 ) $ (0.30 )
 
       
Three Months Ended June 30, Six Months Ended June 30,
2018     2017 2018     2017
Numerator:
Net loss attributable to vTv Therapeutics Inc. $ (3,072 ) $ (3,963 ) $ (6,024 ) $ (8,183 )
Reallocation of net income attributable to non-controlling

interest from the assumed exchange of Class B shares (1)

  (6,524 )   (9,451 )   (13,532 )   (19,517 )
Net loss before noncontrolling interest $ (9,596 ) $ (13,414 ) $ (19,556 ) $ (27,700 )
Denominator:
Weighted-average number of vTv Therapeutics Inc.

Class A Common Stock, basic and diluted

10,049,831 9,693,254 9,875,743 9,693,254
Assumed exchange of Class B Common Stock (1)   23,094,221     23,119,246     23,104,867     23,119,246  
Adjusted proforma fully exchanged weighted-average

shares of Class A common stock outstanding,

basic and diluted

  33,144,052     32,812,500     32,980,610     32,812,500  
Adjusted proforma earnings per fully exchanged share,

basic and diluted

$ (0.29 ) $ (0.41 ) $ (0.59 ) $ (0.84 )
 
(1)   Assumes the exchange of all outstanding Class B common stock, resulting in the elimination of the non-controlling interest and recognition of the net income attributable to non-controlling interests.
 

http://www.businesswire.com/news/home/20180803005081/en/vTv-Therapeutics-Announces-Quarter-2018-Results-Update/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

bluebird bio to Present at the 2018 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass.–()–bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the 2018 Wedbush PacGrow Healthcare Conference, Tuesday, August 14, at 8:35 a.m. ET at the Parker New York Hotel, New York City.

To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the conference.

About bluebird bio, Inc.

With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio (Nasdaq: BLUE) has built a pipeline with broad potential application in severe genetic diseases and cancer.

bluebird bio’s gene therapy clinical programs include investigational treatments for cerebral adrenoleukodystrophy, transfusion-dependent β-thalassemia, also known as β-thalassemia major, and severe sickle cell disease.

bluebird bio’s oncology pipeline is built upon the company’s lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. The company’s lead oncology programs are anti-BCMA CAR T programs partnered with Celgene.

bluebird bio’s discovery research programs include utilizing megaTAL/homing endonuclease gene editing technologies with the potential for use across the company’s pipeline.

bluebird bio has operations in Cambridge, Massachusetts; Seattle, Washington; Durham, North Carolina and Zug, Switzerland.

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s product candidates and research programs. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks that the preliminary results from our clinical trials will not continue or be repeated in our ongoing clinical trials, the risk of cessation or delay of any of the ongoing or planned clinical studies and/or our development of our product candidates, the risk of a delay in the enrollment of patients in our clinical studies, risks that the current or planned clinical trials of the LentiGlobin drug product will be insufficient to support regulatory submissions or marketing approval in the United States and European Union, the risk that our collaborations, including the collaboration with Celgene, will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed, approved or commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

http://www.businesswire.com/news/home/20180803005054/en/bluebird-bio-Present-2018-Wedbush-PacGrow-Healthcare/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

The Kraft Heinz Company Declares Regular Quarterly Dividend of $0.625 Per Share

PITTSBURGH & CHICAGO–()–The Board of Directors of The Kraft Heinz Company (NASDAQ: KHC) today declared a regular quarterly dividend of $0.625 per share of common stock payable on Sept. 14, 2018, to stockholders of record as of Aug. 17, 2018.

ABOUT THE KRAFT HEINZ COMPANY

The Kraft Heinz Company (NASDAQ: KHC) is the fifth-largest food and beverage company in the world. A globally trusted producer of delicious foods, The Kraft Heinz Company provides high quality, great taste and nutrition for all eating occasions whether at home, in restaurants or on the go. The Company’s iconic brands include Kraft, Heinz, ABC, Capri Sun, Classico, Jell-O, Kool-Aid, Lunchables, Maxwell House, Ore-Ida, Oscar Mayer, Philadelphia, Planters, Plasmon, Quero, Smart Ones and Velveeta. The Kraft Heinz Company is dedicated to the sustainable health of our people, our planet and our Company. For more information, visit www.kraftheinzcompany.com.

http://www.businesswire.com/news/home/20180803005058/en/Kraft-Heinz-Company-Declares-Regular-Quarterly-Dividend/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

Global Lower Limb Muscle Spasticity Ongoing Clinical Trials – Analysis & Outlook to 2022 – ResearchAndMarkets.com

DUBLIN–()–The “Lower Limb Muscle Spasticity Ongoing Global Clinical Trials Analysis and Outlook” report has been added to ResearchAndMarkets.com‘s offering.

Lower Limb Muscle Spasticity ongoing clinical trials report provides comprehensive analysis and trends in global Lower Limb Muscle Spasticity disease clinical trials. The research work analyzes the ongoing Lower Limb Muscle Spasticity clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Lower Limb Muscle Spasticity treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Lower Limb Muscle Spasticity clinical trials.

Scope of the Report:

  • Ongoing Lower Limb Muscle Spasticity clinical trials across regions
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Lower Limb Muscle Spasticity
  • Both observational and interventional trials analyzed
  • Leading companies and universities participating in Lower Limb Muscle Spasticity clinical trials

Reasons to Buy:

  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market

Key Topics Covered:

1 Table of Contents

2 Key Findings, 2018

3 Clinical Trials Trends to 2022

4 Country Level Analysis

5 Company Level Analysis

6 Enrolment Trends to 2022

7 Ongoing Trials- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company Details

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/x79qbl/global_lower_limb?w=4

http://www.businesswire.com/news/home/20180803005223/en/Global-Limb-Muscle-Spasticity-Ongoing-Clinical-Trials/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

Diligent adquiere Brainloop para ampliar Governance Cloud, la oferta de gobernanza en la nube, con espacios de datos virtuales seguros para empresas

NUEVA YORK–()–Diligent Corporation (“Diligent” o “la Compañía”), líder en soluciones de gestión de gobierno corporativo y el proveedor más fiable de soluciones seguras de colaboración ejecutiva, ha anunciado hoy la finalización de la adquisición de Brainloop, un proveedor líder de software de espacios de datos virtuales dedicado a la colaboración de alta seguridad en documentos confidenciales. Con sede en Múnich, Brainloop se convertirá en el centro neurálgico de Diligent para el continente europeo y seguirá siendo dirigido por el equipo de gestión actual, incluido el CEO Thomas Deutschmann y el director de tecnología Eike Schmidt. Las condiciones financieras de la transacción no han sido reveladas.

Brainloop es un proveedor líder de almacenamiento seguro en la nube para empresas, que opera en Alemania y toda Europa continental, y que está comprometido con la protección de los datos más importantes y sensibles de los clientes a través de aplicaciones altamente seguras, soluciones de comunicación eficientes, colaboración e intercambio de información confidencial. La compañía se fundó en el año 2000 y hoy sirve a miles de usuarios en seis continentes, incluidas algunas de las principales compañías europeas.

Como empresa del grupo Diligent, Brainloop continuará operando de forma independiente y sirviendo a sus clientes bajo su marca, mientras aprovecha las oportunidades que ofrecen los recursos sólidos de Diligent a escala internacional. Brainloop mantendrá los datos de sus clientes en sus centros de datos seguros actuales en toda Europa. Más de la mitad de los ingresos de Diligent se generan fuera de Estados Unidos, y ahora, en combinación con Brainloop, la compañía se convertirá en la herramienta profesional líder para unas comunicaciones y colaboración seguras en Europa continental. Juntos, Diligent y Brainloop, ofrecerán a una base de clientes internacional un conjunto de productos altamente complementarios, entre los que se incluyen la oferta de gobernanza en la nube (Governance Cloud) líder en el sector de Diligent y las salas de datos virtuales altamente seguras de Brainloop.

“Diligent se compromete a ofrecer a las juntas y equipos de administración las herramientas necesarias para una gestión empresarial segura y efectiva, y estamos entusiasmados con esta nueva oportunidad de ampliar nuestra oferta de gobernanza en la nube a lo largo de toda la estructura empresarial”, ha afirmado Brian Stafford, presidente y CEO de Diligent.

“Hace tiempo que admiramos la confianza y la excelente reputación que tienen en Europa Thomas Deutschmann y Brainloop gracias a sus espacios de datos virtuales y sus soluciones de colaboración sumamente seguras. Juntos apuntaremos a fortalecer la presencia de Diligent en el mercado de habla alemana, de alto crecimiento, y en toda Europa, ofreciendo a nuestros clientes productos caracterizados por la excelencia y los más altos estándares de seguridad”.

“Para Brainloop, la seguridad y protección de datos siempre han sido extremadamente importantes y estamos encantados de encontrar en Diligent un socio igual de interesado que nosotros en la seguridad y privacidad de la información del cliente”, ha comentado Thomas Deutschmann, CEO de Brainloop. “Diligent estaba buscando un espacio de datos virtual para expandirse a escala internacional, y nos sentimos muy orgullosos de que lo hayan encontrado en Brainloop. Nuestro objetivo es ofrecer a los clientes, en colaboración con el equipo de Diligent, una solución más completa para administrar el gobierno corporativo”.

District Capital Partners actuó como asesor financiero, Willkie Farr & Gallagher LLP, como asesor legal, y Spitzberg Partners como asesor estratégico de Diligent. ARQUIS actuó como asesor legal, fiscal y financiero de Brainloop.

Acerca de Diligent Corporation

Diligent es líder en administración de gobierno corporativo y brinda soluciones seguras de gobierno y colaboración corporativos a juntas y altos directivos a través de su oferta de gobierno en la nube. Más de 14.000 clientes en más de 90 países de los siete continentes confían en Diligent para ofrecer una distribución segura de los materiales de la junta, así como envíos seguros, cumplimiento integrado, evaluación de la junta y gestión de entidades. Governance Cloud es la única solución que cumple con las necesidades en evolución de las principales organizaciones. Visite www.diligent.com para más información.

Acerca de Brainloop

Fundada en 2000, Brainloop es un proveedor líder de soluciones SaaS (software-as-a-service) altamente intuitivas. Estas soluciones permiten a sus clientes gestionar y colaborar de forma segura en documentos e información confidenciales, tanto dentro como fuera de la empresa. Los clientes de Brainloop abarcan numerosas empresas incluidas en los índices Fortune, FTSE y DAX y pertenecientes a una amplia gama de sectores privados y públicos. Estos clientes confían en las capacidades de Brainloop en cuanto a cumplimiento, colaboración y procesos normativos y corporativos, así como en su completa cartera de características de seguridad, tales como cifrado completo, seguimiento de auditoría, autenticación de dos factores y protección de proveedores y administradores, elementos que se combinan con una interfaz cómoda y fácil de usar. Para obtener más información, visite http://www.brainloop.com.

El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ayuda y deberá ser comparada con el texto en idioma original, que es la única versión del texto que tendrá validez legal.

http://www.businesswire.com/news/home/20180803005224/es/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

Role of Customer Care in Improving Customer Experience | Infiniti Research

LONDON–()–Infiniti Research, a world-renowned market intelligence solutions provider, has announced the completion of their latest article on the role of customer care in improving customer experience.

Modern businesses that want to flourish in today’s tremendously competitive marketplace are taking the old phrase ‘caveat venditor’ (meaning let the seller beware) seriously. Customer care and satisfaction have now become the keystone for evaluating success in businesses. Typically, customer care services, which include call centers as well as self-service and online channels, play an essential role in a company. As the natural owner of a large part of the customer journey, customer care can offer priceless insights by helping businesses find pain points, describe journeys, and spur collaboration across functions.

To know more about the scope of our engagement, request a proposal.

Customer experience (CX) includes customers’ communications with an organization, both in the pre- and post-sale phase. The customer experience strategy describes the actionable plans that have to bring a positive and meaningful experience to the customers throughout those interactions. Organizations that are successful in executing a good customer experience strategy offer a better customer journey, have increased customer satisfaction rates and revenues, and experience reduced churn.

“Having a good customer experience strategy is a great tool to gain an upper hand in the market and build better goodwill for your brand,” says an industry expert from Infiniti.

Role of customer care in improving customer experience:

  • Formulate strategies from customer journey data: A substantial number of touchpoints across principal channels are supervised by customer care. This makes customer care the obvious owner of several service-focused customer journeys. Other significant functional teams in the company such as marketing, sales, and product development can use these insights while implementing their strategies and subsequently ensure a better customer experience. To know more about our solutions, get in touch.
  • Implement improvement measures: Customers report their problems or concerns about the company’s products and services to the customer care. This allows organizations to take the necessary action and prepare a better customer experience strategy, either for one particular journey or different common touchpoints in all journeys. To know more about our solutions for the role of customer care in improving customer experience, request a proposal.
  • Indicator of customer loyalty and repurchase: The customer care service and customer experience provided by firms is a major determining factor of customer loyalty towards a brand. Organizations that do not give preference to customer care will observe the lowest rate of good CX and a higher rate of customer churn.
  • Get in touch, to know more about the role of customer care in improving customer experience.

Infiniti Research is a global market intelligence company offering strategic insights to help look beyond market disruptions, study competitive activity, and develop intelligent business strategies. Listed below are the role of customer care in improving customer experience.

View the complete list of the role of customer care in improving customer experience:

https://www.infinitiresearch.com/thoughts/customer-care-strategies-customer-experience

About Infiniti Research

Established in 2003, Infiniti Research is a leading market intelligence company providing smart solutions to address your business challenges. Infiniti Research studies markets in more than 100 countries to help analyze competitive activity, see beyond market disruptions, and develop intelligent business strategies.

With 15+ years of experience and offices across three continents, Infiniti Research has been instrumental in providing a complete range of competitive intelligence, strategy, and research services for over 550 companies across the globe.

http://www.businesswire.com/news/home/20180803005192/en/Role-Customer-Care-Improving-Customer-Experience-Infiniti/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

Global Liver Failure Ongoing Clinical Trials – Analysis & Outlook to 2022 – ResearchAndMarkets.com

DUBLIN–()–The “Liver Failure Ongoing Global Clinical Trials Analysis and Outlook” report has been added to ResearchAndMarkets.com‘s offering.

Liver Failure ongoing clinical trials report provides comprehensive analysis and trends in global Liver Failure disease clinical trials. The research work analyzes the ongoing Liver Failure clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Liver Failure treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Liver Failure clinical trials.

Scope of the Report:

  • Ongoing Liver Failure clinical trials across regions
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Liver Failure
  • Both observational and interventional trials analyzed
  • Leading companies and universities participating in Liver Failure clinical trials

Reasons to Buy:

  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market

Key Topics Covered:

1 Table of Contents

2 Key Findings, 2018

3 Clinical Trials Trends to 2022

4 Country Level Analysis

5 Company Level Analysis

6 Enrolment Trends to 2022

7 Ongoing Trials- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company Details

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/ggjvkn/global_liver?w=4

http://www.businesswire.com/news/home/20180803005225/en/Global-Liver-Failure-Ongoing-Clinical-Trials–/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

Selective Soldering Equipment Procurement Report: US Market Insights and Procurement Best Practices Information Now Available from SpendEdge

LONDON–()–Global procurement market intelligence advisory firm, SpendEdge, has announced the release of their Global Selective Soldering Equipment Category – Procurement Market Intelligence Category. This report offers insights into the supply market and highlights key category growth drivers from the perspective of the buyers and the suppliers. Additionally, it suggests the top suppliers of selective soldering equipment. According to the procurement report, the spend growth momentum for this category will accelerate owing to an increased preference for SMT over the through-hole technology for mounting electronic components on to PCBs.

SpendEdge’s procurement market intelligence reports for the heavy industry category analyze the category maturity across regions, which highlights the key cost drivers for the buyers. Insights into the category ecosystem will also help determine the operational capability matrix for the suppliers. Additionally, SpendEdge’s reports offer insights on the sustainability and procurement best practices for the category.

In the selective soldering equipment supply market, the buyers should engage with suppliers who offer short-term rental plans or long-term lease plans. These help small buyers that incur high capital expenditure for purchasing a selective soldering machine,” says SpendEdge procurement expert Anil Seth.

Looking for more procurement insights from this report? Request a FREE sample report.

SpendEdge sample reports are free of charge and provide insights that focus on the cost-saving aspects of procurement and the optimization of category spend.

The procurement experts at SpendEdge expect the following factors to play a key role in influencing the global category spend for the selective soldering equipment market.

  • Rising demand for automobiles, consumer electronics, and white goods
  • Rising demand for convenience and comfort
  • To know more, request a FREE sample report.

This report is available at USD 1000 discount for a limited time only: View the full report before purchasing.

SpendEdge is now offering limited-time discounts for bundled report purchases. Buy TWO reports at discounted rates and get the THIRD one for FREE.

Report scope snapshot: Selective soldering equipment market.

Market Insights

Best Practices

Category Ecosystem

Do you purchase multiple reports in a year? Our subscription platform, SpendEdge Insights, provides ready-to-use procurement research reports for multiple categories, latest supplier news, innovation landscape, markets insights, supplier tracking, and much more at the click of a button. Start your 14-day FREE trial now.

Related Reports:

About SpendEdge

SpendEdge shares your passion for driving sourcing and procurement excellence. We are a preferred procurement market intelligence partner for Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence that helps sourcing and procurement professionals make informed decisions. These innovative procurement solutions help enterprises transform structural capabilities, improve execution efficiency, and fast-track time to savings.

http://www.businesswire.com/news/home/20180803005162/en/Selective-Soldering-Equipment-Procurement-Report-Market-Insights/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

Kraft Heinz Reports Second Quarter 2018 Results

PITTSBURGH & CHICAGO–()–The Kraft Heinz Company (NASDAQ: KHC) (“Kraft Heinz” or the “Company”) today reported second quarter 2018 financial results that reflected favorable impacts from acquisitions net of divestitures and currency, as well as higher input costs and increased investments to enhance capabilities.

“Our results through the first half were stronger than the expectations we put forward as recently as three months ago, and we have been even more encouraged by our recent performance in the marketplace,” said Kraft Heinz CEO Bernardo Hees. “We believe we are now in a position to drive sustainable top-line growth from a strong pipeline of new product, marketing and whitespace initiatives that are backed by investments in capabilities for brand and category advantage. And while cost inflation on many fronts has been holding back our bottom line, we expect our profitability to improve by year-end, with further momentum into 2019.”

Q2 2018 Financial Summary

 

For the Three Months Ended

 

Year-over-year Change

     

Impact of

 
June 30, July 1,

    Impact of    

Acquisitions and

2018 2017

      Actual      

Currency Divestitures

    Organic    

(in millions, except per share data)
Net sales $ 6,686 $ 6,637 0.7% 0.3 pp 0.8 pp (0.4 )%
Operating income 1,329 1,644 (19.1)%
Net income/(loss) attributable to common shareholders 756 1,159 (34.8)%
Diluted EPS $ 0.62 $ 0.94 (34.0)%
Adjusted EBITDA(1) 1,974 2,065 (4.4)% 0.4 pp
Adjusted EPS(1) $ 1.00 $ 0.98 2.0%

Net sales were $6.7 billion, up 0.7 percent versus the year-ago period, including a favorable 0.3 percentage point impact from currency and a net 0.8 percentage point benefit from acquisitions and divestitures. Organic Net Sales decreased 0.4 percent versus the year-ago period. Pricing increased 1.3 percentage points, driven by pricing to offset local input costs in Rest of World markets and higher pricing in North America that more than offset increased in-store and new product activity in EMEA. Volume/mix decreased 1.7 percentage points, as lower shipments in North America more than offset growth in EMEA and gains from condiments and sauces in Rest of World markets.

Net income attributable to common shareholders decreased to $756 million and diluted EPS decreased to $0.62, primarily due to non-cash impairment charges in the current period, versus non-cash curtailment gains recognized in the prior year period related to the Integration Program. Adjusted EBITDA decreased 4.4 percent versus the year-ago period to $2.0 billion, including a favorable 0.4 percentage point impact from currency. Excluding the impact of currency, Adjusted EBITDA declined primarily due to higher input costs, lower volume/mix and investments in strategic initiatives. Adjusted EPS increased 2.0 percent to $1.00, primarily driven by lower taxes on adjusted earnings in the current period.

Q2 2018 Business Segment Highlights

United States

            For the Three Months Ended   Year-over-year Change
     

Impact of

 
June 30, July 1,

  Impact of  

Acquisitions and

2018 2017

      Actual      

Currency Divestitures

    Organic    

(in millions)
Net sales $ 4,513 $ 4,601 (1.9)% 0.0 pp 0.0 pp (1.9 )%
Segment Adjusted EBITDA 1,432 1,557 (8.0)% 0.0 pp

United States net sales were $4.5 billion, down 1.9 percent versus the year-ago period. Pricing increased 0.4 percentage points, as higher pricing in select categories was partially offset by the timing of trade spend, as well as lower pricing to reflect declines in certain key commodity(2) costs, particularly bacon. Volume/mix decreased 2.3 percentage points driven by lower shipments in cheese, frozen and nuts, which was partially offset by growth in ready-to-drink beverages.

United States Segment Adjusted EBITDA decreased 8.0 percent versus the year-ago period to $1.4 billion, primarily reflecting non-key commodity cost inflation, lower volume/mix, and capability investments that were partially offset by gains from productivity and higher pricing.

Canada

            For the Three Months Ended   Year-over-year Change
     

Impact of

 
June 30, July 1,

  Impact of  

Acquisitions and

2018 2017

      Actual      

Currency Divestitures

    Organic    

(in millions)

 

Net sales $ 564 $ 592 (4.5)% 3.7 pp 0.0 pp (8.2 )%
Segment Adjusted EBITDA 172 189 (8.9)% 3.4 pp

Canada net sales were $564 million, 4.5 percent lower than the year-ago period, reflecting a favorable 3.7 percentage point impact from currency and an 8.2 percent decline in Organic Net Sales. Pricing increased 0.6 percentage points, primarily driven by higher pricing in condiments and sauces. Volume/mix decreased 8.8 percentage points due to prior year promotional activity that was not repeated, primarily in condiments and sauces, as well as trade inventory adjustments and select product discontinuations.

Canada Segment Adjusted EBITDA decreased 8.9 percent versus the year-ago period to $172 million, including a favorable 3.4 percentage point impact from currency. Excluding currency, Segment Adjusted EBITDA decreased primarily due to lower volume/mix.

EMEA(3)

           

For the Three Months Ended

  Year-over-year Change
     

Impact of

 
June 30, July 1,

  Impact of  

Acquisitions and

2018 2017

      Actual      

Currency Divestitures

    Organic    

(in millions)
Net sales $ 703 $ 647 8.7% 5.4 pp (0.7) pp 4.0 %
Segment Adjusted EBITDA 201 184 8.9% 6.0 pp

EMEA net sales were $703 million, up 8.7 percent versus the year-ago period, including a 5.4 percentage point benefit from currency and a negative 0.7 percentage point impact from the divestiture of a joint venture in South Africa. Organic Net Sales increased 4.0 percent versus the year-ago period. Pricing declined 1.0 percentage points to support in-store and new product activity in condiments and sauces, as well as infant nutrition that more than offset higher pricing in meals. Volume/mix increased 5.0 percentage points, driven by growth in condiments and sauces, including the addition of Kraft products in certain regions within the segment, as well as strong foodservice gains in every region.

EMEA Segment Adjusted EBITDA increased 8.9 percent versus the year-ago period to $201 million, including a positive 6.0 percentage point impact from currency. Excluding the impact of currency, Segment Adjusted EBITDA increased 2.9 percent, as gains from productivity were partially offset by higher overhead costs and lower pricing.

Rest of World(3)(4)

            For the Three Months Ended   Year-over-year Change
     

Impact of

 
June 30, July 1,

  Impact of  

Acquisitions and

2018 2017

      Actual      

Currency Divestitures

    Organic    

(in millions)
Net sales $ 906 $ 797 13.5% (5.4) pp 8.1 pp 10.8 %
Segment Adjusted EBITDA 213 171 24.6% (7.1) pp

Rest of World net sales were $906 million, increasing 13.5 percent versus the year-ago period, including a negative 5.4 percentage point impact from currency and an 8.1 percentage point contribution from the Cerebos acquisition. Organic Net Sales increased 10.8 percent versus the year-ago period. Pricing was up 9.2 percentage points, primarily due to actions to offset input cost inflation in local currency, particularly in Latin America. Volume/mix increased 1.6 percentage points, as strong growth in condiments and sauces across a majority of regions was partially offset by lower shipments in Southeast Asia and negative impacts from a truck drivers’ strike in Brazil.

Rest of World Segment Adjusted EBITDA increased 24.6 percent versus the year-ago period to $213 million, despite a negative 7.1 percentage point impact from currency. Excluding the impact of currency, Segment Adjusted EBITDA increased 31.7 percent driven by Organic Net Sales gains that were partially offset by higher input costs in local currency.

End Notes

(1)   Organic Net Sales, Adjusted EBITDA, Constant Currency Adjusted EBITDA and Adjusted EPS are non-GAAP financial measures. Please see discussion of non-GAAP financial measures and the reconciliations at the end of this press release for more information.
 
(2) The Company’s key commodities in the United States and Canada are dairy, meat, coffee and nuts.
 
(3) In the first quarter of the Company’s fiscal year 2018, the Company reorganized certain of its international businesses to better align the Company’s global geographies. As a result, Middle East and Africa businesses were moved from the historical Asia Pacific, Middle East, and Africa (“AMEA”) operating segment into the historical Europe reportable segment, forming the new Europe, Middle East, and Africa (“EMEA”) reportable segment. The remaining businesses from the AMEA operating segment became the Asia Pacific (“APAC”) operating segment. This change has been reflected in all historical periods presented.
 
(4) Rest of World comprises two operating segments: Latin America and APAC.
 

Webcast and Conference Call Information

A webcast of The Kraft Heinz Company’s second quarter 2018 earnings conference call will be available at ir.kraftheinzcompany.com. The call begins today at 8:30 a.m. Eastern Time.

ABOUT THE KRAFT HEINZ COMPANY

The Kraft Heinz Company (NASDAQ: KHC) is the fifth-largest food and beverage company in the world. A globally trusted producer of delicious foods, The Kraft Heinz Company provides high quality, great taste and nutrition for all eating occasions whether at home, in restaurants, or on the go. The Company’s iconic brands include Kraft, Heinz, ABC, Capri Sun, ClassicoJell-OKool-Aid, Lunchables, Maxwell House, Ore-Ida, Oscar Mayer, Philadelphia, Planters, Plasmon, Quero, Smart Ones and Velveeta. The Kraft Heinz Company is dedicated to the sustainable health of our people, our planet and our Company. For more information, visit www.kraftheinzcompany.com.

Forward-Looking Statements

This press release contains a number of forward-looking statements. Words such as “enhance,” “encouraged,” “believe,” “position,” “anticipate,” “reflect,” “invest,” “see,” “make,” “expect,” “deliver,” “drive,” “improve,” “assess,” “evaluate,” “grow,” “will,” and variations of such words and similar future or conditional expressions are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements regarding the Company’s plans, segment changes, cost savings, expectations, investments, innovations, opportunities, capabilities, execution, initiatives, and growth. These forward-looking statements are not guarantees of future performance and are subject to a number of risks and uncertainties, many of which are difficult to predict and beyond the Company’s control.

Important factors that may affect the Company’s business and operations and that may cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, operating in a highly competitive industry; changes in the retail landscape or the loss of key retail customers; the Company’s ability to maintain, extend and expand its reputation and brand image; the impacts of the Company’s international operations; the Company’s ability to leverage its brand value to compete against retailer brands and other economy brands; the Company’s ability to predict, identify and interpret changes in consumer preferences and demand; the Company’s ability to drive revenue growth in its key product categories, increase its market share, or add products; an impairment of the carrying value of goodwill or other indefinite-lived intangible assets; volatility in commodity, energy and other input costs; changes in the Company’s management team or other key personnel; the Company’s ability to realize the anticipated benefits from its cost savings initiatives; changes in relationships with significant customers and suppliers; the execution of the Company’s international expansion strategy; tax law changes or interpretations; legal claims or other regulatory enforcement actions; product recalls or product liability claims; unanticipated business disruptions; the Company’s ability to complete or realize the benefits from potential and completed acquisitions, alliances, divestitures or joint ventures; economic and political conditions in the United States and in various other nations in which we operate; volatility of capital markets and other macroeconomic factors; increased pension, labor and people-related expenses; volatility in the market value of all or a portion of the derivatives we use; exchange rate fluctuations; risks associated with information technology and systems, including service interruptions, misappropriation of data or breaches of security; the Company’s ability to protect intellectual property rights; impacts of natural events in the locations in which we or the Company’s customers, suppliers or regulators operate; the Company’s indebtedness and ability to pay such indebtedness; the Company’s ownership structure; the impact of future sales of the Company’s common stock in the public markets; the Company’s ability to continue to pay a regular dividend; restatements of the Company’s consolidated financial statements; and other factors. For additional information on these and other factors that could affect the Company’s forward-looking statements, see the Company’s risk factors, as they may be amended from time to time, set forth in its filings with the Securities and Exchange Commission. The Company disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation.

Non-GAAP Financial Measures

To supplement the financial information, the Company has presented Organic Net Sales, Adjusted EBITDA, Constant Currency Adjusted EBITDA, and Adjusted EPS, which are considered non-GAAP financial measures. The non-GAAP financial measures provided should be viewed in addition to, and not as an alternative for, results prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) that are presented in this press release. The non-GAAP financial measures presented may differ from similarly titled non-GAAP financial measures presented by other companies, and other companies may not define these non-GAAP financial measures in the same way. These measures are not substitutes for their comparable GAAP financial measures, such as net sales, net income/(loss), diluted earnings per share, or other measures prescribed by GAAP, and there are limitations to using non-GAAP financial measures.

Management uses these non-GAAP financial measures to assist in comparing the Company’s performance on a consistent basis for purposes of business decision making by removing the impact of certain items that management believes do not directly reflect the Company’s underlying operations. Management believes that presenting the Company’s non-GAAP financial measures is useful to investors because it (i) provides investors with meaningful supplemental information regarding financial performance by excluding certain items, (ii) permits investors to view performance using the same tools that management uses to budget, make operating and strategic decisions, and evaluate historical performance, and (iii) otherwise provides supplemental information that may be useful to investors in evaluating the Company’s results. The Company believes that the presentation of these non-GAAP financial measures, when considered together with the corresponding GAAP financial measures and the reconciliations to those measures, provides investors with additional understanding of the factors and trends affecting the Company’s business than could be obtained absent these disclosures.

Organic Net Sales is defined as net sales excluding, when they occur, the impact of currency, acquisitions and divestitures, and a 53rd week of shipments. The Company calculates the impact of currency on net sales by holding exchange rates constant at the previous year’s exchange rate, with the exception of Venezuela, for which the Company calculates the previous year’s results using the current year’s exchange rate. Organic Net Sales is a tool that can assist management and investors in comparing the Company’s performance on a consistent basis by removing the impact of certain items that management believes do not directly reflect the Company’s underlying operations.

Adjusted EBITDA is defined as net income/(loss) from continuing operations before interest expense, other expense/(income), net, provision for/(benefit from) income taxes, and depreciation and amortization (excluding integration and restructuring expenses); in addition to these adjustments, the Company excludes, when they occur, the impacts of integration and restructuring expenses, deal costs, unrealized losses/(gains) on commodity hedges, impairment losses, losses/(gains) on the sale of a business, nonmonetary currency devaluation (e.g., remeasurement gains and losses), and equity award compensation expense (excluding integration and restructuring expenses). The Company also presents Adjusted EBITDA on a constant currency basis. The Company calculates the impact of currency on Adjusted EBITDA by holding exchange rates constant at the previous year’s exchange rate, with the exception of Venezuela, for which it calculates the previous year’s results using the current year’s exchange rate. Adjusted EBITDA and Constant Currency Adjusted EBITDA are tools that can assist management and investors in comparing the Company’s performance on a consistent basis by removing the impact of certain items that management believes do not directly reflect the Company’s underlying operations.

Adjusted EPS is defined as diluted earnings per share excluding, when they occur, the impacts of integration and restructuring expenses, deal costs, unrealized losses/(gains) on commodity hedges, impairment losses, losses/(gains) on the sale of a business, nonmonetary currency devaluation (e.g., remeasurement gains and losses), and U.S. Tax Reform discrete income tax expense/(benefit), and including when they occur, adjustments to reflect preferred stock dividend payments on an accrual basis. The Company believes Adjusted EPS provides important comparability of underlying operating results, allowing investors and management to assess operating performance on a consistent basis.

See the attached schedules for supplemental financial data, which includes the financial information, the non-GAAP financial measures and corresponding reconciliations to the comparable GAAP financial measures for the relevant periods.

       

Schedule 1

The Kraft Heinz Company
Condensed Consolidated Statements of Income
(in millions, except per share data)
(Unaudited)
 
For the Three Months Ended     For the Six Months Ended
June 30,   July 1, June 30,   July 1,
2018 2017 2018 2017
Net sales $ 6,686 $ 6,637 $ 12,990 $ 12,961
Cost of products sold(a) 4,321   4,204   8,380   8,329  
Gross profit 2,365 2,433 4,610 4,632
Selling, general and administrative expenses(b) 1,036   789   1,800   1,555  
Operating income 1,329 1,644 2,810 3,077
Interest expense 318 307 635 620
Other expense/(income), net(c) (35 ) (253 ) (125 ) (383 )
Income/(loss) before income taxes 1,046 1,590 2,300 2,840
Provision for/(benefit from) income taxes 291   430   552   789  
Net income/(loss) 755 1,160 1,748 2,051
Net income/(loss) attributable to noncontrolling interest (1 ) 1   (1 ) (1 )
Net income/(loss) attributable to common shareholders $ 756   $ 1,159   $ 1,749   $ 2,052  
 
Basic shares outstanding 1,219 1,218 1,219 1,218
Diluted shares outstanding 1,226 1,229 1,227 1,229
 
Per share data applicable to common shareholders:
Basic earnings/(loss) per share $ 0.62 $ 0.95 $ 1.43 $ 1.69
Diluted earnings/(loss) per share 0.62 0.94 1.43 1.67

(a)

 

Integration and restructuring expenses recorded in cost of products sold were $79 million for the quarter ended June 30, 2018 ($69 million after-tax), $83 million for the quarter ended July 1, 2017 ($59 million after-tax), $157 million for the six months ended June 30, 2018 ($130 million after-tax), and $179 million for the six months ended July 1, 2017 ($125 million after-tax).

 

(b)

Integration and restructuring expenses recorded in selling, general and administrative expenses (“SG&A”) were $14 million for the quarter ended June 30, 2018 ($12 million after-tax), $71 million for the quarter ended July 1, 2017 ($50 million after-tax), $26 million for the six months ended June 30, 2018 ($22 million after-tax), and $110 million for the six months ended July 1, 2017 ($76 million after-tax).

 

(c)

Integration and restructuring expenses/(income) recorded in other expense/(income), net were expenses of $64 million for the quarter ended June 30, 2018 ($53 million after-tax), income of $160 million for the quarter ended July 1, 2017 ($111 million after-tax), expenses of $64 million for the six months ended June 30, 2018 ($53 million after-tax), and income of $147 million for the six months ended July 1, 2017 ($102 million after-tax).

 
           

Schedule 2

The Kraft Heinz Company
Reconciliation of Net Sales to Organic Net Sales
For the Three Months Ended
(dollars in millions)
(Unaudited)
 

Impact of

   
Impact of

Acquisitions and

Organic Net

  Net Sales  

Currency   Divestitures Sales

      Price      

Volume/Mix
June 30, 2018
United States $ 4,513 $ $ $ 4,513
Canada 564 21 543
EMEA 703 35 11 657
Rest of World 906   (4 ) 63 847
$ 6,686   $ 52   $ 74 $ 6,560
 
July 1, 2017
United States $ 4,601 $ $ $ 4,601
Canada 592 592
EMEA 647 15 632
Rest of World 797   33   764
$ 6,637   $ 33   $ 15 $ 6,589
 
Year-over-year growth rates
United States (1.9 )% 0.0 pp 0.0 pp (1.9)% 0.4 pp (2.3) pp
Canada (4.5 )% 3.7 pp 0.0 pp (8.2)% 0.6 pp (8.8) pp
EMEA 8.7 % 5.4 pp (0.7) pp 4.0% (1.0) pp 5.0 pp
Rest of World 13.5 % (5.4) pp 8.1 pp 10.8% 9.2 pp 1.6 pp
Kraft Heinz 0.7 % 0.3 pp 0.8 pp (0.4)% 1.3 pp (1.7) pp
 
           

Schedule 3

The Kraft Heinz Company
Reconciliation of Net Sales to Organic Net Sales
For the Six Months Ended
(dollars in millions)
(Unaudited)
 

Impact of

   
Impact of

Acquisitions and

Organic Net

    Net Sales    

Currency Divestitures Sales

      Price      

Volume/Mix
June 30, 2018
United States $ 8,881 $ $ $ 8,881
Canada 1,048 43 1,005
EMEA 1,388 109 19 1,260
Rest of World 1,673   13 63 1,597
$ 12,990   $ 165 $ 82 $ 12,743
 
July 1, 2017
United States $ 9,119 $ $ $ 9,119
Canada 1,032 1,032
EMEA 1,244 31 1,213
Rest of World 1,566   73 1,493
$ 12,961   $ 73 $ 31 $ 12,857
 
Year-over-year growth rates
United States (2.6 )% 0.0 pp 0.0 pp (2.6)% 0.6 pp (3.2) pp
Canada 1.6 % 4.1 pp 0.0 pp (2.5)% 0.4 pp (2.9) pp
EMEA 11.6 % 8.8 pp (1.0) pp 3.8% (0.8) pp 4.6 pp
Rest of World 6.8 % (4.3) pp 4.1 pp 7.0% 6.8 pp 0.2 pp
Kraft Heinz 0.2 % 0.7 pp 0.4 pp (0.9)% 1.1 pp (2.0) pp
 
       

Schedule 4

The Kraft Heinz Company
Reconciliation of Net Income/(Loss) to Adjusted EBITDA
(dollars in millions)
(Unaudited)
 
For the Three Months Ended     For the Six Months Ended
June 30,   July 1, June 30,   July 1,
2018 2017 2018 2017
Net income/(loss) $ 755 $ 1,160 $ 1,748 $ 2,051
Interest expense 318 307 635 620
Other expense/(income), net (35 ) (253 ) (125 ) (383 )
Provision for/(benefit from) income taxes 291   430   552   789  
Operating income 1,329 1,644 2,810 3,077
Depreciation and amortization (excluding integration and restructuring expenses) 242 218 448 440
Integration and restructuring expenses 93 154 183 289
Deal costs 7 16
Unrealized losses/(gains) on commodity hedges 3 (13 ) 5 29
Impairment losses 265 48 265 48
Losses/(gains) on sale of business 15 15
Equity award compensation expense (excluding integration and restructuring expenses) 20   14   27   26  
Adjusted EBITDA $ 1,974   $ 2,065   $ 3,769   $ 3,909  
 
Segment Adjusted EBITDA:
United States $ 1,432 $ 1,557 $ 2,814 $ 3,021
Canada 172 189 306 314
EMEA 201 184 383 324
Rest of World 213 171 356 315
General corporate expenses (44 ) (36 ) (90 ) (65 )
Adjusted EBITDA $ 1,974   $ 2,065   $ 3,769   $ 3,909  
 
           

Schedule 5

The Kraft Heinz Company
Reconciliation of Adjusted EBITDA to Constant Currency Adjusted EBITDA
For the Three Months Ended
(dollars in millions)
(Unaudited)
 

             Adjusted            

   

            Impact of            

   

  Constant Currency  

EBITDA Currency Adjusted EBITDA
June 30, 2018
United States $ 1,432 $ $ 1,432
Canada 172 6 166
EMEA 201 12 189
Rest of World 213 1 212
General corporate expenses (44 ) (1 ) (43 )
$ 1,974   $ 18   $ 1,956  
 
July 1, 2017
United States $ 1,557 $ $ 1,557
Canada 189 189
EMEA 184 184
Rest of World 171 10 161
General corporate expenses (36 )   (36 )
$ 2,065   $ 10   $ 2,055  
 
Year-over-year growth rates
United States (8.0 )% 0.0 pp (8.0 )%
Canada (8.9 )% 3.4 pp (12.3 )%
EMEA 8.9 % 6.0 pp 2.9 %
Rest of World 24.6 % (7.1) pp 31.7 %
General corporate expenses 22.8 % 2.8 pp 20.0 %
Kraft Heinz (4.4 )% 0.4 pp (4.8 )%
 
           

Schedule 6

The Kraft Heinz Company
Reconciliation of Adjusted EBITDA to Constant Currency Adjusted EBITDA
For the Six Months Ended
(dollars in millions)
(Unaudited)
 

            Adjusted            

   

            Impact of            

   

  Constant Currency  

EBITDA Currency Adjusted EBITDA
June 30, 2018
United States $ 2,814 $ $ 2,814
Canada 306 12 294
EMEA 383 32 351
Rest of World 356 4 352
General corporate expenses (90 ) (3 ) (87 )
$ 3,769   $ 45   $ 3,724  
 
July 1, 2017
United States $ 3,021 $ $ 3,021
Canada 314 314
EMEA 324 324
Rest of World 315 21 294
General corporate expenses (65 )   (65 )
$ 3,909   $ 21   $ 3,888  
 
Year-over-year growth rates
United States (6.9 )% 0.0 pp (6.9 )%
Canada (2.5 )% 3.9 pp (6.4 )%
EMEA 18.2 % 9.8 pp 8.4 %
Rest of World 13.1 % (6.5) pp 19.6 %
General corporate expenses 37.3 % 3.8 pp 33.5 %
Kraft Heinz (3.6 )% 0.6 pp (4.2 )%
 
             

Schedule 7

The Kraft Heinz Company
Reconciliation of Diluted EPS to Adjusted EPS
(Unaudited)
 
For the Three Months Ended     For the Six Months Ended
June 30, July 1, June 30, July 1,
2018 2017 2018 2017
Diluted EPS $ 0.62 $ 0.94 $ 1.43 $ 1.67
Integration and restructuring expenses(a)(c) 0.11 0.17 0.08
Deal costs(a)(b) 0.01
Unrealized losses/(gains) on commodity hedges(a)(b) (0.01 ) 0.01
Impairment losses(a)(b) 0.20 0.03 0.20 0.03
Losses/(gains) on sale of business(a)(b) 0.01 0.01
Nonmonetary currency devaluation(a)(d) 0.02 0.02 0.05 0.03
U.S. Tax Reform discrete income tax expense/(benefit)(e) 0.04   0.02
Adjusted EPS $ 1.00 $ 0.98   $ 1.89 $ 1.82

(a)

 

Income tax expense associated with these items is based on applicable jurisdictional tax rates and deductibility assessments of individual items.

(b)

Refer to the reconciliation of net income/(loss) to Adjusted EBITDA for the related gross expenses.

(c)

Integration and restructuring included the following gross expenses/(income):

 

Expenses recorded in cost of products sold were expenses of $79 million for the three months and $157 million for the six months ended June 30, 2018 and $83 million for the three months and $179 million for the six months ended July 1, 2017.

Expenses recorded in SG&A were $14 million for the three months and $26 million for the six months ended June 30, 2018 and $71 million for the three months and $110 million for the six months ended July 1, 2017.

 

Expenses/(income) recorded in other expense/(income), net, were expenses of $64 million for the three and six months ended June 30, 2018 and income of $160 million for the three months and $147 million for the six months ended July 1, 2017.

(d)

Nonmonetary currency devaluation included the following gross expenses:

Expenses recorded in other expense/(income), net, were $20 million for the three months and $67 million for the six months ended June 30, 2018 and $25 million for the three months and $33 million for the six months ended July 1, 2017.

(e)

U.S. Tax Reform discrete income tax expense/(benefit) included expenses of $44 million for the three months and $24 million for the six months ended June 30, 2018 (there were no such expenses for the three or six months ended July 1, 2017). Expenses for the three and six months ended June 30, 2018 primarily related to the revaluation of our deferred tax balances due to changes in state tax laws following U.S. Tax Reform. Expenses for the six months ended were partially offset by U.S. Tax Reform measurement period adjustments in the first quarter of 2018.

 
               

Schedule 8

The Kraft Heinz Company
Condensed Consolidated Balance Sheets
(in millions, except per share data)
(Unaudited)
   

        June 30, 2018        

  December 30, 2017  

ASSETS
Cash and cash equivalents $ 3,369 $ 1,629
Trade receivables, net 1,950 921
Sold receivables 37 353
Income taxes receivable 177 582
Inventories 3,161 2,815
Other current assets 807   966  
Total current assets 9,501 7,266
Property, plant and equipment, net 7,258 7,120
Goodwill 44,270 44,824
Intangible assets, net 59,101 59,449
Other assets 1,766   1,573  
TOTAL ASSETS $ 121,896   $ 120,232  
 
LIABILITIES AND EQUITY
Commercial paper and other short-term debt $ 34 $ 460
Current portion of long-term debt 2,754 2,743
Trade payables 4,326 4,449
Accrued marketing 474 680
Income taxes payable 88 152
Interest payable 404 419
Other current liabilities 1,011   1,229  
Total current liabilities 9,091 10,132
Long-term debt 31,380 28,333
Deferred income taxes 14,230 14,076
Accrued postemployment costs 394 427
Other liabilities 929   1,017  
TOTAL LIABILITIES 56,024 53,985
 
Redeemable noncontrolling interest 7 6
Equity:
Common stock, $0.01 par value 12 12
Additional paid-in capital 58,766 58,711
Retained earnings 8,710 8,589
Accumulated other comprehensive income/(losses) (1,557 ) (1,054 )
Treasury stock, at cost (254 ) (224 )
Total shareholders’ equity 65,677 66,034
Noncontrolling interest 188   207  
TOTAL EQUITY 65,865   66,241  
TOTAL LIABILITIES AND EQUITY $ 121,896   $ 120,232  

http://www.businesswire.com/news/home/20180803005116/en/Kraft-Heinz-Reports-Quarter-2018-Results/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

CBIZ Small Business Employment Index Follows Historical Summer Decline for July

CLEVELAND–()–The CBIZ Small Business Employment Index (SBEI), which tracks hiring trends among thousands of companies that employ 300 or fewer employees across the U.S., reported a month-over-month decrease in hiring of 2.03 percent in July, following an increase in hiring of 1.73 percent in June.

“July historically shows a seasonal decline in hiring as employers reach full staffing for the requisite summer months’ demand,” says Philip Noftsinger, Executive Vice President at CBIZ Employee Benefits. “However, this July represents a larger decline than most, indicating there may be more at work. That statistic doesn’t necessarily mean that the economic growth cycle is at an end, however.”

ADP and Moody’s Analytics reported Wednesday that the private sector posted an employment increase of 219,000 month-over-month, on a seasonally adjusted basis. Small businesses accounted for 52,000 of those jobs and the report found that almost all sectors and industries reported an increase.

To view an infographic with data from the employment index, visit the CBIZ blog.1

Additional takeaways from the July SBEI include:

  • July’s snapshot: When compared to the June reading, 21 percent of companies increased their headcounts, 49 percent refrained from making labor changes, and 30 percent decreased their employee totals. Since the SBEI’s inception in June 2009, the July reading has seen an average hiring decrease of 0.99 percent, and this year’s reading is the second-largest decline during the July period.
  • Industries at a glance: Of the industries reflected in the index, Agriculture grew notably, which is common during the summer months, followed by Insurance and Wholesale Distribution. Meanwhile, Transportation, Education, Non-Profits, and Accommodation and Food Services declined, and Construction recorded a nearly flat figure with a 0.11 percent decline.
  • Geographical hiring: The entire country experienced hiring declines in July, with the Northeast, Central, Southeast and West regions posting declines of 0.77 percent, 2.11 percent, 1.65 percent and 3.74 percent, respectively.
  • What’s next? According to the National Federation of Independent Business, more employers than ever are hiring or attempting to hire workers. However, the ability to find qualified workers is their single-largest business concern. This could mean we are quickly approaching the final stages of slack in the labor market, and as participation reaches its maximum potential, given our workforce population, wages may begin to increase.

CBIZ Payroll Services manages payroll services for more than 4,000 businesses. Its index reflects a broad array of industries and geographies corresponding to the markets across the U.S. where CBIZ provides human capital services. The data represented by the SBEI is derived from a segment of employers not completely accounted for by the ADP and federal Bureau of Labor Statistics employment reports.

Editor’s note:

(1) The SBEI illustration is licensed under a Creative Commons Attribution-NoDerivs 3.0 Unported License. Based on our work at http://www.cbiz.com/insights-resources/blog.

Follow CBIZ on Twitter at @CBZ or on Facebook.

About CBIZ, Inc.

CBIZ, Inc. provides professional business services that help clients better manage their finances and employees. CBIZ provides its clients with financial services including accounting, tax, financial advisory, government health care consulting, risk advisory, real estate consulting and valuation services. Employee services include employee benefits consulting, property and casualty insurance, retirement plan consulting, payroll, life insurance, HR consulting and executive recruitment. As one of the largest accounting, insurance brokerage and valuation companies in the United States, the company’s services are provided through more than 100 company offices in 33 states. CBIZ Employee Services Organization is a division of CBIZ Benefits & Insurance Services, Inc.

http://www.businesswire.com/news/home/20180803005042/en/CBIZ-Small-Business-Employment-Index-Historical-Summer/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

GOGO SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Gogo Inc. – GOGO

NEW ORLEANS–()–ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 27, 2018 to file lead plaintiff applications in a securities class action lawsuit against Gogo Inc. (NasdaqGS: GOGO), if they purchased the Company’s securities between February 27, 2017 and May 7, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

Get Help

Gogo investors should visit us at https://www.claimsfiler.com/cases/view-gogo-inc-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.

About the Lawsuit

Gogo and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On May 4, 2018, the Company disclosed disappointing quarterly earnings results including that it would be unable to meet EBITDA profit guidance of $75M-$100M, was withdrawing “its previously provided 2018 guidance for Adjusted EBITDA, airborne Cash CAPEX, and airborne equipment inventory purchases related to airline-directed installations, as well as Free Cash Flow guidance.” Then, on May 7, 2018, post-market, Moody’s announced a downgrade of the Company’s credit rating.

On this news, the price of Gogo’s shares plummeted.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler’s team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

http://www.businesswire.com/news/home/20180803005522/en/GOGO-SHAREHOLDER-ALERT-ClaimsFiler-Reminds-Investors-Losses/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

SEABOARD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Seaboard Corporation – SEB

NEW ORLEANS–()–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Seaboard Corporation (NYSE: SEB).

Since September 2014, the Company has been the recipient of numerous subpoenas and informal inquiries by the U.S. Department of Justice (“DOJ”) seeking information relating to foreign entities as well as an affiliate of Seaboard, including a 2017 probe into money transfers and bank accounts in the Democratic Republic of Congo and other African countries for which the DOJ also seeks “to interview certain Seaboard employees and to obtain testimony before a grand jury.” In February 2016, the Company revealed it was being investigated by the U.S. Environmental Protection Agency (“EPA”) under the Clean Air Act with regard to ammonia releases at an Oklahoma processing plant, disclosing later in December 2017 that it had settled the violations by “agreeing to pay a civil penalty and to implement a supplemental environmental project, the aggregate amount of both totaling less than $1 million.”

KSF’s investigation is focusing on whether Seaboard’s officers and/or directors breached their fiduciary duties to Seaboard’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Seaboard shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-seb/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

http://www.businesswire.com/news/home/20180803005515/en/SEABOARD-INVESTIGATION-INITIATED-Louisiana-Attorney-General-Kahn/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

CHARTER INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charter Communications, Inc. – CHTR

NEW ORLEANS–()–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Charter Communications, Inc. (NasdaqGS: CHTR).

On February 1, 2017, the New York Attorney General filed suit against Charter and its subsidiary Spectrum Management Holdings, LLC (formerly Time Warner Cable, Inc., which was acquired by Charter in May 2016), for fraudulently misleading consumers by promising internet service that they knew they could not deliver. Charter’s attempt to dismiss the suit was denied and the case remains ongoing.

Then, on July 27, 2018, the New York State Public Service Commission announced it had revoked approval of the Company’s 2016 merger and its permission to operate in the state because it failed to honor an agreement that was part of the merger to build out internet access to rural areas of New York, stating that Charter “had multiple opportunities to correct these issues and either has not done so or has been openly brazen in its efforts to avoid them.” Further, the commission is seeking $3 million in penalties and has given the Company two months to find a replacement provider for its cable operations.

KSF’s investigation is focusing on whether Charter’s officers and/or directors breached their fiduciary duties to Charter’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-time holder of Charter shares, and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-chtr/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

http://www.businesswire.com/news/home/20180803005506/en/CHARTER-INVESTIGATION-INITIATED-Louisiana-Attorney-General-Kahn/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

PAPA JOHN’S INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Papa John’s International, Inc. – PZZA

NEW ORLEANS–()–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Papa John’s International, Inc. (NasdaqGS: PZZA).

On July 10, 2018, public outrage over media reports that Schnatter had used a racial slur during a conference call in May 2018 resulted in his resignation as Chairman of the Board. Soon after, Schnatter publicly voiced his regret over the resignation and his intention to oppose efforts by the Board to further limit his involvement with the Company, leading to a battle between he and the Board (on which he still retains a seat) that is ongoing, with Schnatter recently filing suit against the Company seeking documents related to his removal and accusing the board of acting negligently or staging a possible “coup.” Further, on July 19, 2018, a report by Forbes highlighted “Papa John’s Toxic Culture,” stating that “Schnatter’s alleged behavior ranges from spying on his workers to sexually inappropriate conduct, which has resulted in at least two confidential settlements,” which it based on “interviews with 37 current and former Papa John’s employees—including numerous executives and board members.”

KSF’s investigation is focusing on whether Papa John’s officers and/or directors breached their fiduciary duties to Papa John’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Papa John’s shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-pzza/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

http://www.businesswire.com/news/home/20180803005507/en/PAPA-JOHN%E2%80%99S-INVESTIGATION-INITIATED-Louisiana-Attorney-General/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

“The Cold Wallet 2.0”? ELLIPAL lanceert mobielgeoriënteerde Cold Wallet voor cryptovaluta

PEKING–()–De meeste cold wallets van dit moment zijn opslaggeoriënteerd en verbonden aan een pc. Dit biedt weinig gebruiksgemak en de risico’s blijven gewoon bestaan. Bezitters van cryptovaluta struinen de markt af op zoek naar de ideale veilige wallet. De ideale wallet voor hen is een veilige tool voor dagelijks handelen die mobiel georiënteerd is, voorzien van alle functies, en compatibel met meerdere valuta. Veiligheid, functionaliteit en gebruiksgemak zijn essentiële eigenschappen voor de volgende generatie van cold wallets.

Een groep getalenteerde blockchainexperts uit Hongkong heeft een nieuwe wallet gelanceerd die beschikt over alle bovenstaande eigenschappen: ELLIPAL. Het is een mobiel georiënteerde cold wallet met alle benodigde functies waarmee kan worden gehandeld. Dit is de start van de volgende generatie van cold wallets. De Cold Wallet 2.0 wordt de essentiële tool voor alle cryptovalutahandelaars.

ELLIPAL – The Cold Wallet 2.0 verbindt iedereen veilig en comfortabel met de blockchain

De naam ELLIPAL is afgeleid van ‘Elli’- Elliptic Curve Cryptography (de kerntechnologie achter de cryptovaluta van vandaag) en ‘Pal’- het Engelse woord voor partner/vriend. ELLIPAL biedt gebruikers een alles-in-één mibiele digital asset management service. ELLIPAL verbindt elke gebruiker met de blockchain.

Kenmerken van ELLIPAL – The Cold Wallet 2.0

  1. Een onafhankelijk hardwareproduct om de veiligheid van cryptovaluta te waarborgen.
    ELLIPAL is een cold wallet. ELLIPAL werkt geïsoleerd van elke internetverbinding, zoals 4G, WiFi, Bluetooth en USB. De enige manier om informatie uit te wisselen tussen de wallet en de mobiele app van ELLIPAL is door middel van QR-codes.
  2. Alles-in-één mobiele app voor het omwisselen en verhandelen van cryptovaluta
    De ELLIPAL-app biedt alle functionaliteit die gebruikers nodig hebben. In de app kunnen gebruikers wisselkoersen raadplegen en nieuws lezen, wisseltransacties en betalingen uitvoeren, en een verbinding maken met andere DApps. ELLIPAL werkt op dit moment samen met gedecentraliseerde wisselprotocols als LRC.
  3. Uniek cross-chain walletprotocol ondersteunt meerdere cryptovaluta en multi-chain
    ELLIPAL heeft een universeel OCCW (Open Cross Chain Wallet) protocol gecreëerd om multi-chain accountsystemen te ondersteunen en te kunnen worden gebruikt voor meerdere cryptovaluta. We geloven dat door dit protocol in de toekomst meer apparaten kunnen worden gebruikt als multifunctionele wallets, zodat blockchain toegankelijker wordt voor de doorsnee gebruiker.
  4. Klaar voor de toekomst van de zakenwereld.
    Het ecosysteem van cryptovaluta breidt zich momenteel in hoog tempo uit. Multivaluta is de norm van de toekomst. De ELLIPAL-walletoplossing maakt de uitwisseling tussen klanten en handelaars eenvoudig en transparant, en heeft een onmiskenbare toegevoegde waarde.

Maak contact met ELLIPAL:

Website: www.ellipal.com

Facebook: https://www.facebook.com/pg/Ellipalclub

Twitter: https://twitter.com/EllipalWallet

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.

http://www.businesswire.com/news/home/20180803005233/nl/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

Global Lewy body Dementia Ongoing Clinical Trials – Analysis & Outlook to 2022 – ResearchAndMarkets.com

DUBLIN–()–The “Lewy body Dementia Ongoing Global Clinical Trials Analysis and Outlook” report has been added to ResearchAndMarkets.com‘s offering.

Lewy body Dementia ongoing clinical trials report provides comprehensive analysis and trends in global Lewy body Dementia disease clinical trials. The research work analyzes the ongoing Lewy body Dementia clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Lewy body Dementia treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Lewy body Dementia clinical trials.

Scope of the Report:

  • Ongoing Lewy body Dementia clinical trials across regions
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Lewy body Dementia
  • Both observational and interventional trials analyzed
  • Leading companies and universities participating in Lewy body Dementia clinical trials

Reasons to Buy:

  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market

Key Topics Covered:

1 Table of Contents

2 Key Findings, 2018

3 Clinical Trials Trends to 2022

4 Country Level Analysis

5 Company Level Analysis

6 Enrolment Trends to 2022

7 Ongoing Trials- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company Details

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/7bvqtb/global_lewy_body?w=4

http://www.businesswire.com/news/home/20180803005234/en/Global-Lewy-body-Dementia-Ongoing-Clinical-Trials/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

Smiths Group Plc UK Regulatory Announcement: Early Redemption

LONDON–()–

Please be advised that the following issue has redeemed early:

ISIN: US83238PAB04 & USG82401AE33

Issuer: Smiths Group plc

Call Date: 04/09/2018

Cash Amount: TBC

Call Price: TBC

Short Name: Smiths Group Plc
Category Code: MSCM
Sequence Number: 652767
Time of Receipt (offset from UTC): 20180803T125343+0100

http://www.businesswire.com/news/home/20180803005237/en/Smiths-Group-Plc-UK-Regulatory-Announcement-Early/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

Global Labor And Delivery Ongoing Clinical Trials – Analysis & Outlook to 2022 – ResearchAndMarkets.com

DUBLIN–()–The “Labor And Delivery Ongoing Global Clinical Trials Analysis and Outlook” report has been added to ResearchAndMarkets.com‘s offering.

Labor And Delivery ongoing clinical trials report provides comprehensive analysis and trends in global Labor And Delivery disease clinical trials. The research work analyzes the ongoing Labor And Delivery clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Labor And Delivery treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Labor And Delivery clinical trials.

Scope of the Report:

  • Ongoing Labor And Delivery clinical trials across regions
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Labor And Delivery
  • Both observational and interventional trials analyzed
  • Leading companies and universities participating in Labor And Delivery clinical trials

Reasons to Buy:

  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market

Key Topics Covered:

1 Table of Contents

2 Key Findings, 2018

3 Clinical Trials Trends to 2022

4 Country Level Analysis

5 Company Level Analysis

6 Enrolment Trends to 2022

7 Ongoing Trials- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company Details

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/dp66zj/global_labor_and?w=4

http://www.businesswire.com/news/home/20180803005238/en/Global-Labor-Delivery-Ongoing-Clinical-Trials–/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa

American Advertising Federation Taps MediaLink to Lead President & CEO Search

WASHINGTON & NEW YORK–()–The American Advertising Federation (AAF) announced today it has engaged MediaLink, an Ascential company, to lead the search for its new President and CEO. The decision follows an announcement in May that longtime AAF President and CEO James Edmund Datri will step down on October 10th after completing 10 years of service to the organization.

MediaLink will work closely with the AAF search committee comprised of several board members and executives. The search will be overseen by Managing Director Trish Shortell, who joined MediaLink in June to lead the strategic advisory firm’s executive search practice.

“As we look to find a President and CEO suited to advance AAF’s impact, an important success marker will be their commitment to next gen talent, to multicultural advancement, and to bringing the industry together to solve our shared challenges.” said Amanda Richman, US CEO, Wavemaker and AAF board chair. “MediaLink has a strong history of identifying leaders capable of reimagining the traditional trade organization model. Their executive search practice has a unique position in the marketplace, giving them first-hand understanding of and access to top talent that can drive lasting change.”

“The AAF is a storied organization that has long supported the interests of every corner of advertising and the industries that touch it,” said Michael Kassan, Chairman and CEO of MediaLink. “As this broad advertising and marketing landscape faces reinvention every day, a forward-thinking, inspirational industry voice is an increasingly crucial resource for talent and businesses. We’re thrilled to help the AAF find its next leader who will become just that for our rapidly transforming industry.”

About the American Advertising Federation

Established in 1905, the American Advertising Federation (AAF), acts as the “Unifying Voice for Advertising.” Its membership is comprised of nearly 100 corporate members made up of the nation’s leading advertisers, agencies, and media companies; a national network of nearly 200 local clubs representing 40,000 advertising professionals; and more than 200 college chapters with 5,000 student members. The AAF operates a host of programs and initiatives, including the Advertising Hall of Fame, the Advertising Hall of Achievement, the American Advertising Awards, the National Student Advertising Competition, the Mosaic Center for Multiculturalism and AdCamp for high school students.

About MediaLink:

MediaLink operates at the intersection of media, marketing, advertising, entertainment, technology and finance, delivering companies the advice, partners and opportunities they need to enable change and drive actionable solutions. Unlike any other company in the strategic advisory space, MediaLink helps companies execute in the core areas of revenue acceleration, industry marketing, investor strategy, data and technology solutions, and talent (including retained Executive Search). Founded in 2003 by Michael E. Kassan, MediaLink employs 150+ professionals in New York, Chicago, Los Angeles, San Francisco, London, Frankfurt and Berlin. MediaLink is an Ascential company. www.medialink.com

About Ascential plc:

Ascential is a global business-to-business information company that informs and connects the business world in 150 countries through market-leading Exhibitions & Festivals and Information Services. Ascential powers the global trend forecasting service WGSN, environmental risk data business Groundsure, e-commerce analytics provider One Click Retail, the prestigious Cannes Lions festival for the branded communications industry, the world’s premier payments and financial services congress Money20/20 and MediaLink, a U.S.-based advisory and business services firm. The company provides customers with world class content and connections empowering their businesses to be the best informed and best connected. www.ascential.com

http://www.businesswire.com/news/home/20180803005221/en/American-Advertising-Federation-Taps-MediaLink-Lead-President/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa